Who Paid My Doc
William Loutfy
Plastic Surgery Albuquerque, NM Medical Doctor
NPI 1659570950 CMS profile 638270
10400 Academy Rd Ne, #230, Albuquerque, NM 87111
General payments
$4,389
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, William Loutfy of Albuquerque, NM is reported in the CMS Open Payments database as having received $4,389 across 151 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 68th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $749 | 20 | |
| 2024 | General | $1,252 | 33 | |
| 2023 | General | $682 | 26 | |
| 2022 | General | $580 | 22 | |
| 2021 | General | $451 | 18 | |
| 2020 | General | $206 | 10 | |
| 2019 | General | $469 | 22 |
Beside peers
- William Loutfy
- Plastic Surgery median
- Middle half of Plastic Surgery
- National median
In program year 2025, general payments to William Loutfy were reported at $749. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.
Show as a table
| Year | William Loutfy | Plastic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $469 | $371 | $122–$1,483 | $163 |
| 2020 | $206 | $158 | $52–$438 | $114 |
| 2021 | $451 | $249 | $87–$752 | $132 |
| 2022 | $580 | $274 | $102–$793 | $149 |
| 2023 | $682 | $299 | $113–$891 | $160 |
| 2024 | $1,252 | $361 | $124–$1,062 | $164 |
| 2025 | $749 | $379 | $138–$1,100 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
148
Drug cost
$624
Branded share of claims
14.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Cephalexin | Generic | 41 | $193 | |
| Baclofen | Generic | 26 | $137 | |
| Promethazine Hcl | Generic | 23 | $124 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 21 | $106 | |
| Clonidine Hcl | Generic | 25 | $39 | |
| Temazepam | Generic | 12 | $25 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 700 Part D prescribers listed as Plastic Surgery; they describe a distribution and say nothing about conduct.
Records
151 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Plastic Surgery in New Mexico
Practitioners in the same specialty and state, ranked by reported value.
All Plastic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in New Mexico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.